Literature DB >> 7468116

Plasma oncotic pressure and plasma protein concentration in patients following thermal injury.

H Zetterström, G Arturson.   

Abstract

Plasma oncotic pressure (POP), albumin and total protein were measured in 14 patients with thermal injuries varying extent from 16 to 90% of the body surface. The patients were treated with large amounts of balanced salt solutions in the initial phase. There was an abrupt, pronounced decrease in POP to about 51% of the normal during the first 24 h. Despite the low POP values (minimum 0.78 kPa) and marked peripheral oedema, no patient had overt pulmonary oedema. Clinical and roentgenological evidence of pulmonary dysfunction during the initial period was only seen in conjunction with lung burn or aspiration pneumonitis. Oedema-preventing mechanism and inability to detect interstitial pulmonary oedema are discussed as possible explanations. There was no significant correlation between decrease in POP and mortality, but low POP values seemed to persist longer in the patients who died.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7468116     DOI: 10.1111/j.1399-6576.1980.tb01550.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  4 in total

1.  Burn resuscitation: is it straightforward or a challenge?

Authors:  S Hayek; A Ibrahim; G Abu Sittah; B Atiyeh
Journal:  Ann Burns Fire Disasters       Date:  2011-03-31

Review 2.  Pathophysiology of burns.

Authors:  Maike Keck; David H Herndon; Lars P Kamolz; Manfred Frey; Marc G Jeschke
Journal:  Wien Med Wochenschr       Date:  2009

Review 3.  Pathogenesis of edema formation in burn injuries.

Authors:  T Lund; H Onarheim; R K Reed
Journal:  World J Surg       Date:  1992 Jan-Feb       Impact factor: 3.352

4.  Plasma volume expansion and capillary leakage of 20% albumin in burned patients and volunteers.

Authors:  Markus Zdolsek; Robert G Hahn; Folke Sjöberg; Joachim H Zdolsek
Journal:  Crit Care       Date:  2020-05-05       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.